Coherus Biosciences Inc. (CHRS) 24.79 $CHRS
Baxter Amends Financial Provisions of Coherus Collaboration - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 10:40AM CDT
Baxter International Inc. (BAX) recently amended certain financial provisions of its collaboration with Coherus BioSciences (CHRS).
SRDX: 26.57 (+0.02), BAX: 70.38 (+0.33), LMAT: 8.44 (-0.10), CHRS: 24.79 (-0.89)
Baxter and Coherus update collaboration agreement for Enbrel biosimilar
Seeking Alpha - at Seeking Alpha - Wed Apr 15, 9:14AM CDT
BAX: 70.38 (+0.33), AMGN: 169.10 (+0.64), CHRS: 24.79 (-0.89)
Coherus BioSciences and Baxter Announce Amendment to Etanercept Biosimilar Collaboration Agreement
GlobeNewswire - Wed Apr 15, 7:00AM CDT
Coherus BioSciences, Inc. (Nasdaq:CHRS) and Baxter International Inc. (NYSE:BAX) today announced that they have amended certain financial terms of their collaboration agreement established in August 2013 regarding the development and commercialization of CHS-0214, an etanercept biosimilar product candidate, for Europe, Canada, Brazil, and certain other markets.
BAX: 70.38 (+0.33), CHRS: 24.79 (-0.89)
Weakness Seen in Coherus Biosciences (CHRS): Stock Tumbles 10.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 7:30AM CDT
Shares of Coherus Biosciences (CHRS) fell by nearly 11% on the day. This continues the recent trend of the company, as the stock is now trading within the volatile price range of $24.6 to $32.9 in the past one-month time frame. So make sure to keep a close watch on this firm in the near future.
AFFX: 12.57 (-0.13), CHRS: 24.79 (-0.89)
Why Coherus BioSciences Inc. Shares Burst Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 01, 12:05PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Coherus BioSciences tumbled...
AMGN: 169.10 (+0.64), ABBV: 64.52 (+0.91), CHRS: 24.79 (-0.89)
Coherus prices upsized equity offering
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 9:02PM CDT
CHRS: 24.79 (-0.89)
Coherus Prices Upsized Public Offering of $120.0 Million of Common Stock
GlobeNewswire - Tue Mar 31, 8:50PM CDT
Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced the pricing of its underwritten public offering of 4,137,931 shares of its common stock at a price to the public of $29.00 per share. All of the shares of the common stock to be sold in the offering will be offered by Coherus. In addition, Coherus has granted the underwriters a 30-day option to purchase up to an additional 620,689 shares of common stock at the public offering price, less the underwriting discount.
CHRS: 24.79 (-0.89)
How Novartis Drug Approval Makes Biosimilar Makers Ripe for Acquisition
at The Street - Tue Mar 31, 8:13AM CDT
Pfizer, Teva and Actavis are potential consolidators, while Momenta, Coherus and Epirus lead the list of likely targets.
EPRS: 8.74 (-0.25), AMGN: 169.10 (+0.64), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62), CHRS: 24.79 (-0.89)
Coherus initiates equity offering
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 3:22PM CDT
CHRS: 24.79 (-0.89)
Coherus Announces Proposed Public Offering of Common Stock
GlobeNewswire - Mon Mar 30, 3:01PM CDT
Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced it has commenced an underwritten public offering of $100,000,000 of shares of its common stock. All of the shares of the common stock to be sold in the offering will be offered by Coherus. In addition, Coherus expects to grant the underwriters a 30-day option to purchase up to an additional $15,000,000 of shares of common stock at the public offering price, less the underwriting discount. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
CHRS: 24.79 (-0.89)
Coherus Biosciences (CHRS) Jumps: Stock Moves Up 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 25, 7:51AM CDT
Coherus Biosciences, Inc. (CHRS) was a big mover last session, as the company saw its shares rise over 6% on the day.
AFFX: 12.57 (-0.13), CHRS: 24.79 (-0.89)
Biosimilar firms move up
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 12:20PM CDT
EPRS: 8.74 (-0.25), PFNX: 15.12 (+0.42), CHRS: 24.79 (-0.89)
Coherus BioSciences up 21% premarket after earnings release
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 7:29AM CDT
CHRS: 24.79 (-0.89)
Coherus BioSciences ups revenues 442% in Q4
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 6:28AM CDT
CHRS: 24.79 (-0.89)
This Market Could Grow 6250% in 10 Years
Cheryl Swanson, The Motley Fool - Motley Fool - Mon Mar 23, 4:44PM CDT
Big Pharma just looked into its future... and saw a whole new era dawning. Last year, 32 large-molecule drugs, called biologics, with combined sales of $51 billion, lost patent protection. This year, another $28 billion worth will join them. ...
JNJ: 100.43 (+0.13), BAX: 70.38 (+0.33), C: 53.10 (+0.62), PFE: 34.93 (+0.04), AMGN: 169.10 (+0.64), ABBV: 64.52 (+0.91), HSP: 87.80 (+0.04), NVS: 103.45 (-0.62), CHRS: 24.79 (-0.89)
Coherus BioSciences reports Q4 results
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 3:14PM CDT
CHRS: 24.79 (-0.89)
Coherus BioSciences Reports Fourth Quarter and Year End 2014 Financial and Operating Results
GlobeNewswire - Mon Mar 23, 3:00PM CDT
Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today reported financial results and reviewed corporate events for the quarter and fiscal year ended December 31, 2014.
CHRS: 24.79 (-0.89)
Next Week In Biotech: Pediatric Safety Ad Comm, BIO Asia, Sinovac Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
FLXN: 18.77 (-0.78), MDT: 78.01 (+0.93), RARE: 66.96 (+2.74), PFE: 34.93 (+0.04), SUPN: 13.67 (-0.10), NRX: 8.00 (-0.27), LLY: 72.30 (+0.09), GSK: 46.57 (-0.67), SVA: 5.06 (+0.10), BLRX: 2.12 (unch), AMPH: 15.08 (-0.13), CHRS: 24.79 (-0.89), JNJ: 100.43 (+0.13), GNVC: 2.86 (-0.11), CYCC: 0.94 (-0.03), AZN: 73.35 (+0.65), DPRX: 12.73 (+0.13), TEVA: 63.01 (-1.15), NBY: 0.66 (-0.01)
Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study
GlobeNewswire - Tue Mar 17, 8:00AM CDT
Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it has finalized the Biologics License Application (BLA) enabling clinical program for CHS-1701, a pegfilgrastim biosimilar candidate, and initiated a pivotal pharmacokinetics and pharmacodynamics (PK/PD) study pursuant to feedback received from the U.S. Food and Drug Administration (FDA) on the CHS-1701 development plan. An additional immunogenicity study is planned in healthy volunteers pursuant to this BLA and is projected to be concluded in 2015 to support submission of the 351(k) (biosimilar) license application for CHS-1701 in Q4 2015 or Q1 2016.
CHRS: 24.79 (-0.89)
Baxter Amends Financial Provisions of Coherus Collaboration - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 10:40AM CDT
Baxter International Inc. (BAX) recently amended certain financial provisions of its collaboration with Coherus BioSciences (CHRS).
SRDX: 26.57 (+0.02), BAX: 70.38 (+0.33), LMAT: 8.44 (-0.10), CHRS: 24.79 (-0.89)
Baxter and Coherus update collaboration agreement for Enbrel biosimilar
Seeking Alpha - at Seeking Alpha - Wed Apr 15, 9:14AM CDT
BAX: 70.38 (+0.33), AMGN: 169.10 (+0.64), CHRS: 24.79 (-0.89)
Coherus BioSciences and Baxter Announce Amendment to Etanercept Biosimilar Collaboration Agreement
GlobeNewswire - Wed Apr 15, 7:00AM CDT
Coherus BioSciences, Inc. (Nasdaq:CHRS) and Baxter International Inc. (NYSE:BAX) today announced that they have amended certain financial terms of their collaboration agreement established in August 2013 regarding the development and commercialization of CHS-0214, an etanercept biosimilar product candidate, for Europe, Canada, Brazil, and certain other markets.
BAX: 70.38 (+0.33), CHRS: 24.79 (-0.89)
Weakness Seen in Coherus Biosciences (CHRS): Stock Tumbles 10.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 7:30AM CDT
Shares of Coherus Biosciences (CHRS) fell by nearly 11% on the day. This continues the recent trend of the company, as the stock is now trading within the volatile price range of $24.6 to $32.9 in the past one-month time frame. So make sure to keep a close watch on this firm in the near future.
AFFX: 12.57 (-0.13), CHRS: 24.79 (-0.89)
Why Coherus BioSciences Inc. Shares Burst Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 01, 12:05PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Coherus BioSciences tumbled...
AMGN: 169.10 (+0.64), ABBV: 64.52 (+0.91), CHRS: 24.79 (-0.89)
Coherus prices upsized equity offering
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 9:02PM CDT
CHRS: 24.79 (-0.89)
Coherus Prices Upsized Public Offering of $120.0 Million of Common Stock
GlobeNewswire - Tue Mar 31, 8:50PM CDT
Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced the pricing of its underwritten public offering of 4,137,931 shares of its common stock at a price to the public of $29.00 per share. All of the shares of the common stock to be sold in the offering will be offered by Coherus. In addition, Coherus has granted the underwriters a 30-day option to purchase up to an additional 620,689 shares of common stock at the public offering price, less the underwriting discount.
CHRS: 24.79 (-0.89)
How Novartis Drug Approval Makes Biosimilar Makers Ripe for Acquisition
at The Street - Tue Mar 31, 8:13AM CDT
Pfizer, Teva and Actavis are potential consolidators, while Momenta, Coherus and Epirus lead the list of likely targets.
EPRS: 8.74 (-0.25), AMGN: 169.10 (+0.64), MNTA: 18.62 (+0.56), NVS: 103.45 (-0.62), CHRS: 24.79 (-0.89)
Coherus initiates equity offering
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 3:22PM CDT
CHRS: 24.79 (-0.89)
Coherus Announces Proposed Public Offering of Common Stock
GlobeNewswire - Mon Mar 30, 3:01PM CDT
Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced it has commenced an underwritten public offering of $100,000,000 of shares of its common stock. All of the shares of the common stock to be sold in the offering will be offered by Coherus. In addition, Coherus expects to grant the underwriters a 30-day option to purchase up to an additional $15,000,000 of shares of common stock at the public offering price, less the underwriting discount. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
CHRS: 24.79 (-0.89)
Coherus Biosciences (CHRS) Jumps: Stock Moves Up 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 25, 7:51AM CDT
Coherus Biosciences, Inc. (CHRS) was a big mover last session, as the company saw its shares rise over 6% on the day.
AFFX: 12.57 (-0.13), CHRS: 24.79 (-0.89)
Biosimilar firms move up
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 12:20PM CDT
EPRS: 8.74 (-0.25), PFNX: 15.12 (+0.42), CHRS: 24.79 (-0.89)
Coherus BioSciences up 21% premarket after earnings release
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 7:29AM CDT
CHRS: 24.79 (-0.89)
Coherus BioSciences ups revenues 442% in Q4
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 6:28AM CDT
CHRS: 24.79 (-0.89)
This Market Could Grow 6250% in 10 Years
Cheryl Swanson, The Motley Fool - Motley Fool - Mon Mar 23, 4:44PM CDT
Big Pharma just looked into its future... and saw a whole new era dawning. Last year, 32 large-molecule drugs, called biologics, with combined sales of $51 billion, lost patent protection. This year, another $28 billion worth will join them. ...
JNJ: 100.43 (+0.13), BAX: 70.38 (+0.33), C: 53.10 (+0.62), PFE: 34.93 (+0.04), AMGN: 169.10 (+0.64), ABBV: 64.52 (+0.91), HSP: 87.80 (+0.04), NVS: 103.45 (-0.62), CHRS: 24.79 (-0.89)
Coherus BioSciences reports Q4 results
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 3:14PM CDT
CHRS: 24.79 (-0.89)
Coherus BioSciences Reports Fourth Quarter and Year End 2014 Financial and Operating Results
GlobeNewswire - Mon Mar 23, 3:00PM CDT
Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today reported financial results and reviewed corporate events for the quarter and fiscal year ended December 31, 2014.
CHRS: 24.79 (-0.89)
Next Week In Biotech: Pediatric Safety Ad Comm, BIO Asia, Sinovac Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
FLXN: 18.77 (-0.78), MDT: 78.01 (+0.93), RARE: 66.96 (+2.74), PFE: 34.93 (+0.04), SUPN: 13.67 (-0.10), NRX: 8.00 (-0.27), LLY: 72.30 (+0.09), GSK: 46.57 (-0.67), SVA: 5.06 (+0.10), BLRX: 2.12 (unch), AMPH: 15.08 (-0.13), CHRS: 24.79 (-0.89), JNJ: 100.43 (+0.13), GNVC: 2.86 (-0.11), CYCC: 0.94 (-0.03), AZN: 73.35 (+0.65), DPRX: 12.73 (+0.13), TEVA: 63.01 (-1.15), NBY: 0.66 (-0.01)
Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study
GlobeNewswire - Tue Mar 17, 8:00AM CDT
Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it has finalized the Biologics License Application (BLA) enabling clinical program for CHS-1701, a pegfilgrastim biosimilar candidate, and initiated a pivotal pharmacokinetics and pharmacodynamics (PK/PD) study pursuant to feedback received from the U.S. Food and Drug Administration (FDA) on the CHS-1701 development plan. An additional immunogenicity study is planned in healthy volunteers pursuant to this BLA and is projected to be concluded in 2015 to support submission of the 351(k) (biosimilar) license application for CHS-1701 in Q4 2015 or Q1 2016.
CHRS: 24.79 (-0.89)
